Garresori H - Search Results

1

Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging.

Edland KH, Tjensvoll K, Oltedal S, Dalen I, Lapin M, Garresori H, Glenjen N, Gilje B, Nordgård O. Edland KH, et al. Among authors: garresori h. Mol Oncol. 2023 Sep;17(9):1857-1870. doi: 10.1002/1878-0261.13472. Epub 2023 Jun 28. Mol Oncol. 2023. PMID: 37341038 Free PMC article.

2

Prognostic value of disseminated tumor cells in unresectable pancreatic ductal adenocarcinoma: a prospective observational study.

Nordgård O, Lapin M, Tjensvoll K, Oltedal S, Edland KH, Neverdahl NB, Fostenes D, Garresori H, Glenjen N, Smaaland R, Gilje B. Nordgård O, et al. Among authors: garresori h. BMC Cancer. 2022 Jun 3;22(1):609. doi: 10.1186/s12885-022-09714-x. BMC Cancer. 2022. PMID: 35659265 Free PMC article.

3

Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer.

Lapin M, Edland KH, Tjensvoll K, Oltedal S, Austdal M, Garresori H, Rozenholc Y, Gilje B, Nordgård O. Lapin M, et al. Among authors: garresori h. Clin Cancer Res. 2023 Apr 3;29(7):1267-1278. doi: 10.1158/1078-0432.CCR-22-3526. Clin Cancer Res. 2023. PMID: 36662807 Free PMC article.

4

Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer.

Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, Javle M, Glenjen NI, Abelseth BK, Gilje B, Nordgård O. Lapin M, et al. Among authors: garresori h. J Transl Med. 2018 Nov 6;16(1):300. doi: 10.1186/s12967-018-1677-2. J Transl Med. 2018. PMID: 30400802 Free PMC article.

5

Novel hybridization- and tag-based error-corrected method for sensitive ctDNA mutation detection using ion semiconductor sequencing.

Tjensvoll K, Lapin M, Gilje B, Garresori H, Oltedal S, Forthun RB, Molven A, Rozenholc Y, Nordgård O. Tjensvoll K, et al. Among authors: garresori h. Sci Rep. 2022 Apr 6;12(1):5816. doi: 10.1038/s41598-022-09698-5. Sci Rep. 2022. PMID: 35388068 Free PMC article.

6

Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma.

Knappskog S, Grob T, Venizelos A, Amstutz U, Hjortland GO, Lothe IM, Kersten C, Hofsli E, Sundlöv A, Elvebakken H, Garresori H, Couvelard A, Svensson J, Sorbye H, Perren A. Knappskog S, et al. Among authors: garresori h. JCO Precis Oncol. 2023 Feb;7:e2200336. doi: 10.1200/PO.22.00336. JCO Precis Oncol. 2023. PMID: 36753687 Free PMC article.

7

Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.

Elvebakken H, Hjortland GO, Garresori H, Andresen PA, Janssen EAM, Vintermyr OK, Lothe IMB, Sorbye H. Elvebakken H, et al. Among authors: garresori h. J Neuroendocrinol. 2023 Apr;35(4):e13256. doi: 10.1111/jne.13256. Epub 2023 Apr 5. J Neuroendocrinol. 2023. PMID: 37017614

8

The overriding role of surgery and tumor grade for long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based cohort study.

Søreide JA, Kvaløy JT, Lea D, Sandvik OM, Al-Saiddi M, Haslerud TM, Garresori H, Karlsen LN, Gudlaugsson E, Søreide K. Søreide JA, et al. Among authors: garresori h. Cancer Rep (Hoboken). 2022 Feb;5(2):e1462. doi: 10.1002/cnr2.1462. Epub 2021 Jun 8. Cancer Rep (Hoboken). 2022. PMID: 34105314 Free PMC article.

9

Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.

Pommergaard HC, Nielsen K, Sorbye H, Federspiel B, Tabaksblat EM, Vestermark LW, Janson ET, Hansen CP, Ladekarl M, Garresori H, Hjortland GO, Sundlöv A, Galleberg R, Knigge P, Kjaer A, Langer SW, Knigge U. Pommergaard HC, et al. Among authors: garresori h. J Neuroendocrinol. 2021 May;33(5):e12967. doi: 10.1111/jne.12967. Epub 2021 Mar 26. J Neuroendocrinol. 2021. PMID: 33769624

10

Arterial events in cancer patients treated with apixaban for venous thrombosis.

Larsen TL, Svalastoga M, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA. Larsen TL, et al. Among authors: garresori h. Thromb Res. 2023 Aug;228:128-133. doi: 10.1016/j.thromres.2023.05.017. Epub 2023 May 25. Thromb Res. 2023. PMID: 37327527

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page